Last call on the HHS peptide policy: 221 comments are in, and here's what happens next

By · Published · 6 min read · 11 sources, 10 checked at the source

AI-generated editorial illustration: a smiling man and woman in athletic wear sit on a riverside bench at sunrise; the man points at a phone, and a gym bag sits beside a small vial labeled BPC-157 and a page dated Nov 13th. Not a real product or real people.

Tonight is the deadline. At 11:59 PM Eastern, the public comment window on HHS's six-peptide compounding policy shuts. [V] That's the draft that put BPC-157, TB-500, semax, epitalon, MOTS-c and KPV on a path to licensed compounding pharmacies, and it has already pulled public companies into the market. [V]

The count is climbing fast. The Federal Register's record for the notice still showed 221 comments at its 4:55 AM CST refresh this morning, up from 190 on Wednesday and 29 last Monday. [V] So what do all those comments do, and what comes after tonight?

Facts are as of November 13, 2026, 5:49 AM CST. Sources, with retrieval dates, are at the bottom.

If you only read one box

  • Comments on docket HHS-OASH-2026-0496 close at 11:59 PM Eastern (10:59 PM Central) on Friday, November 13. [V]
  • The Federal Register's nested count still reads 221; regulations.gov last showed 115 posted for public view at 1:47 AM CST, so roughly a hundred are sent in but not yet posted. [V] [U]
  • In the 115 I've read, 112 back the policy in some form, most through one form letter that also asks HHS to add thymosin alpha-1. [U]
  • HHS hasn't said when it will respond. The notice calls the text a draft, so a revised version is possible. [V] [U]

A late wave of support

Two numbers tell the story of this docket. Regulations.gov, where HHS posts comments for the public, last showed 115 at 1:47 AM CST, unchanged since November 7. [V] A later direct check of that posted count was blocked. [U] The Federal Register's separate count, which it pulls from regulations.gov, has gone from 29 on November 9 to 190 on November 11 and 221 at its 4:55 AM CST refresh this morning. [V] My read is that a big batch has arrived and is waiting in HHS's posting queue. [U]

What's already public leans heavily one way. I tagged all 115 posted comments in the docket tracker: 102 are copies of one form letter backing a licensed clinician and compounding-pharmacy route, and asking HHS to reconsider peptides left off the list, with thymosin alpha-1 named most. [V] By my count, 112 of the 115 support the policy in some form. [U] Two oppose it, both arguing HHS is moving ahead of FDA's own review. [V]

  • - 221comments in the Federal Register's count, 4:55 AM CST, Nov. 13 [V]
  • - 115comments posted for public view on regulations.gov, last verified 1:47 AM CST, Nov. 13 [V]
  • - 112 of 115posted comments that back the policy in some form, by my reading [U]

That lines up with what's happening outside the docket. Enhanced says all six peptides went live on its platform by prescription on November 3, DataMEDS AI says its Corexa Pharmacy has made a first sale, and Hims & Hers says its Peptides+ launch starts later this month. [V] The peptide rush tracker keeps the scoreboard.

What the comments can and can't do

A comment isn't a vote. HHS published the policy as a notice of availability, not a rule, and the notice carries no effective date. [V] What comments can do is feed the record. HHS's policy text says public comments "may provide additional evidence that FDA can consider in rulemaking" on the 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry bulks list, the permanent list of ingredients compounders can use. [V]

That matters because the bigger prize is permanence. An enforcement-discretion policy is a statement about where regulators will and won't act; a spot on the 503A bulks list is written into regulation. [V] That process is slow. FDA's 2019 proposal to add five substances is still listed as awaiting a final rule. [V]

After tonight: three things to watch

1. Whether HHS posts a revised policy. The Federal Register notice calls the document a "draft" policy, while HHS's appendix calls it interim. [V] That wording leaves room for changes after the comments are read, but HHS hasn't published a timetable. [U] If it finalizes the policy close to its current form, wider prescription access looks likely, because the companies above are already set up to offer it. [U]

2. Whether the list grows. Thymosin alpha-1 is the clear favorite in the form letter, with kisspeptin-10 and ipamorelin also named. [V] Any addition would need HHS to say so in writing. Until then, the list is six. [V]

3. The quality fight. USP said on November 3 that the policy lacks essential quality safeguards, and a testing business in the docket wants the original maker named on every certificate of analysis. [V] Expect quality rules, not access, to be where HHS spends its revision ink. [U] The USP explainer has the details.

Where this leaves BPC-157

BPC-157 is the name most people know from the six, and its legal picture keeps getting clearer. It isn't a DEA controlled substance. [V] FDA's warning letters have gone to sellers, and I found no federal case against a person for personal possession. [V] [U] The HHS draft opens a prescription lane through state-licensed 503A pharmacies, one patient at a time. [V] For the full answer, see BPC-157: is it legal? The 2026 answer. Tested athletes are a separate story: WADAWorld Anti-Doping Agency: it publishes the yearly Prohibited List for tested sport. Glossary entry still prohibits it. [S]

What I couldn't confirm

  • How many comments HHS actually received. The 221 figure is the Federal Register's pull from regulations.gov, and HHS can hold back duplicates or off-topic submissions from posting. [U]
  • When HHS will respond, or whether it will publish a summary of the comments. [U]
  • Whether trade groups or medical societies filed late. None appear among the 115 posted so far. [V]

Peptide Policy Watch

Last call on the HHS peptide policy: 221 comments are in, and here's what happens next

Published November 13, 2026 · https://peptidepolicywatch.com/2026/11/13/hhs-peptide-comment-period-closes-what-happens-next/

Printable checklist

Worth raising with a prescriber once the dust settles

General questions drawn from this page, to take to a clinician or pharmacist who knows your health history.

  1. If HHS finalizes the policy, would you prescribe any of the six, and through which pharmacy?
  2. Does that pharmacy meet every condition in the HHS draft, including the certificate of analysis?
  3. Is there an FDA-approved option for what I'm hoping to address?
  4. How would a side effect get reported to FDA?

Print view Select it, then use your browser’s Print command to print only this box.

I'll post the final tally in the docket tracker once HHS finishes posting what came in, and I'll update this page the day HHS says anything about next steps.

Sources (retrieved November 13, 2026)

  1. Federal Register API, document 2026-22192, retrieved November 13, 2026, 5:49 AM CST (nested comments_count 221; checked_regulationsdotgov_at November 13, 2026, 4:55 AM CST) [V] — https://www.federalregister.gov/api/v1/documents/2026-22192.json
  2. Regulations.gov public data service, comment search for docket HHS-OASH-2026-0496, last verified November 13, 2026, 1:47 AM CST (meta.totalElements 115); a 5:49 AM CST direct API recheck was blocked [V] [U] — https://www.regulations.gov/docket/HHS-OASH-2026-0496
  3. Federal Register, notice of availability, 91 FR 68526, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496, published October 30, 2026 (comment period ends 11:59 PM Eastern, November 13, 2026) [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  4. HHS, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," with Appendices A and B, October 28, 2026 [V] — https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  5. Peptide Policy Watch docket tally of all 115 posted comments, last read November 9, 2026 (CSV) [V] — https://peptidepolicywatch.com/data/hhs-docket-comments.csv
  6. Enhanced Group Inc., "Enhanced Provides Clinician-Led Access to Six New Peptides," company release, November 3, 2026 [V] — https://investors.enhanced.com/enhanced-provides-clinician-led-access-to-six-new-peptides/
  7. DataMEDS AI, release on Corexa Pharmacy's first commercial sale of compounded peptides, ACCESS Newswire, November 9, 2026 [V] — https://www.accessnewswire.com/newsroom/en/blockchain-and-cryptocurrency/datameds-ai-announces-corexa-pharmacys-first-commercial-sale-of-compo-1248766
  8. Hims & Hers, CEO letter on Peptides+, newsroom, November 9, 2026 [V] — https://news.hims.com/newsroom/how-were-building-the-customer-relationship-in-health
  9. USP, "USP statement on quality and safety considerations for unapproved peptides," November 3, 2026 [V] — https://www.usp.org/news/usp-statement-on-quality-and-safety-considerations-for-unapproved-peptides
  10. FDA, "Bulk Drug Substances Used in Compounding Under Section 503A," page content current as of May 14, 2026 [V] — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  11. WADA, 2026 Prohibited List [S] — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
Cite or link to this page

Peptide Policy Watch staff. “Last call on the HHS peptide policy: 221 comments are in, and here's what happens next.” Peptide Policy Watch. Published November 13, 2026. https://peptidepolicywatch.com/2026/11/13/hhs-peptide-comment-period-closes-what-happens-next/

Link: https://peptidepolicywatch.com/2026/11/13/hhs-peptide-comment-period-closes-what-happens-next/

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits